title: Medullary thyroid cancer: an update for surgeons.
abstract: Medullary thyroid carcinoma is uncommon but accounts for approximately 4 to 5 per cent of all thyroid cancers. Although most cases are sporadic, close to one-fourth of cases result from germline mutations in the RET proto-oncogene. These mutations are clinically important because they predict the earliest age of medullary thyroid cancer diagnosis and clinical aggressiveness, which guide individualized management. This review covers the presentation, diagnosis, workup, current management, and future directions of the management of medullary thyroid carcinoma. Today's chance for cure depends on early and appropriate surgical resection. Further investigation of the cellular signaling pathways shown to be essential for the growth and spread of medullary thyroid carcinoma remains an active field with hope for providing targeted systemic therapy for patients with progressive disease.
authors.affiliation: Department of Surgery, Johns Hopkins University, Baltimore, Maryland, USA.
authors.forename: Faris K
authors.initials: FK
authors.lastname: Azar
authors.forename: Stephanie L
authors.initials: SL
authors.lastname: Lee
authors.forename: Jennifer E
authors.initials: JE
authors.lastname: Rosen
mesh_terms: D018276:Carcinoma, Medullary / Q000175:diagnosis / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D018450:Disease Progression; D005820:Genetic Testing; D018095:Germ-Line Mutation; D006801:Humans; D008197:Lymph Node Excision; D011379:Prognosis; D000090063:Proto-Oncogene Mas; D051096:Proto-Oncogene Proteins c-ret / Q000235:genetics; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D013965:Thyroidectomy
chemical_list: C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D051096:Proto-Oncogene Proteins c-ret